User profiles for J. S. Leeder

J Steven Leeder

Professor of Pediatrics, Children's Mercy Hospitals and Clinics
Verified email at cmh.edu
Cited by 25401

Developmental pharmacology—drug disposition, action, and therapy in infants and children

…, SW Alander, DL Blowey, JS Leeder… - … England Journal of …, 2003 - Mass Medical Soc
For those using drugs to treat infants and children, the integration of developmental pharmacology
is crucial to appropriate clinical practice. Changes in metabolic capacity, distribution …

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake …

…, Y Ji, SG Leckband, JS Leeder… - Clinical …, 2015 - Wiley Online Library
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major
depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the …

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update

…, HM Dunnenberger, JS Leeder… - Clinical …, 2014 - Wiley Online Library
Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450
2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity…

Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor

…, H Dadi, M Shahar, E Arpaia, Z Lapidot, JS Leeder… - Nature, 1996 - nature.com
ACUTE lymphoblastic leukaemia (ALL) is the most common cancer of childhood. Despite
the progress achieved in its treatment, 20% of cases relapse and no longer respond to …

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

…, LD Bradford, MJ Kennedy, JS Leeder - Clinical …, 2008 - Wiley Online Library
Inferring CYP2D6 phenotype from genotype is increasingly challenging, considering the
growing number of alleles and their range of activity. This complexity poses a challenge in …

Cytochrome P450 3A: ontogeny and drug disposition

SN de Wildt, GL Kearns, JS Leeder… - Clinical …, 1999 - Springer
The maturation of organ systems during fetal life and childhood exerts a profound effect on
drug disposition. The maturation of drug-metabolising enzymes is probably the predominant …

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

…, AA Vinks, Y He, JJ Swen, JS Leeder… - Clinical …, 2015 - Wiley Online Library
Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic
stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate …

[HTML][HTML] Prediction of CYP2D6 phenotype from genotype across world populations

…, K Sangkuhl, M Whirl-Carrillo, T Klein, JS Leeder - Genetics in …, 2017 - nature.com
… , to ensure continued support, we are displaying the site without styles and JavaScript. …
Brown JT, Abdel-Rahman SM, van Haandel L, Gaedigk A, Lin YS, Leeder JS. Single dose, …

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy

…, HM Dunnenberger, JS Leeder… - Clinical …, 2021 - Wiley Online Library
Opioids are mainly used to treat both acute and chronic pain. Several opioids are metabolized
to some extent by CYP2D6 (codeine, tramadol, hydrocodone, oxycodone, and methadone…

Glucuronidation in humans: pharmacogenetic and developmental aspects

SN de Wildt, GL Kearns, JS Leeder… - Clinical …, 1999 - Springer
During human development impressive changes in drug disposition occur. An important
determinant of drug clearance is metabolism, something that is not only determined by …